Medigene AG
Medigene AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative immunotherapies for cancer treatment. Founded in 1997, Medigene has established itself as a leader in the field, particularly in the areas of T cell immunotherapy and personalised medicine. With a strong operational presence in Europe and North America, the company is renowned for its unique core products, including its proprietary T cell receptor (TCR) technology, which enables the targeting of specific cancer cells. Medigene's commitment to advancing cancer therapies has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a result, Medigene AG continues to be at the forefront of the biopharmaceutical industry, driving innovation in cancer treatment.
DitchCarbon Score
How does Medigene AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medigene AG's score of 30 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medigene AG's reported carbon emissions
In 2023, Medigene AG reported total carbon emissions of approximately 458,590 kg CO2e, with all emissions classified under Scope 1. There were no reported emissions for Scope 2 or Scope 3, indicating a focus on direct emissions from owned or controlled sources. This represents a reduction from 2022, when emissions were about 492,850 kg CO2e, showcasing a positive trend in their carbon footprint management. Despite these reductions, Medigene AG has not established specific reduction targets or commitments through initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges. The absence of such targets suggests that while the company is actively monitoring its emissions, it may not yet be engaging in formalised climate commitments or long-term reduction strategies. Medigene AG's emissions data is not cascaded from any parent organisation, indicating that the reported figures are solely reflective of its own operations. The company continues to focus on its direct emissions, with no current initiatives reported for broader scope emissions reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 492,850 | 000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medigene AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
